Abstract
Recent advances in the molecular genetic of adrenal tumors give new insights in the pathophysiology of these neoplasms in both hereditary and sporadic cases. The practice of genetic counselling in patients with adrenal tumors have been recently changed by the identification and the understanding of new specific hereditary cancer susceptibility syndromes. In the case of sporadic adrenocortical tumors these progress also offer new prognosis predictors.The genetic predisposition to adrenocortical cancer in children has been well established in the Li-Fraumeni and Beckewith-Wiedeman syndromes due to germline p53 mutation located at 17p13 and dysregulation of the imprinted IGF-2 locus at 11p15, respectively. Adrenocortical tumors are also observed in Multiple Endocrine Neoplasia type I syndrome. Cushing's syndrome due to primary pigmented nodular adrenocortical disease have been observed in patients with germline PRKAR1A inactivating mutations. Interestingly allelic loss at 17p13 and 11p15 have been observed in sporadic adrenocortical cancer and somatic PRKAR1A mutations in secreting adrenocortical adenomas. The potential interest of these finding for the diagnosis of these tumors will be discussed. In the case of pheochromocytoma and paraganglioma, the demonstration that three genes encoding three succinate dehydrogenase subunits (SDHD, SDHB, SDHC), belonging to the complex II of the respiratory chain in the mitochondria, are involved in the genetics of familial and especially in apparently sporadic phaeochromocytomas have dramatically modified our practice. Up to date, four diagnosis of familal disease (multiple endocrine neoplasia type II, von Hippel Lindau disease, neurofibromatosis type 1 and hereditary paraganglioma) should be discussed and causative mutations in six different phaechomocytoma susceptibility genes (RET, VHL, NF1, SDHB, SDHD, SDHC) could be identified. In this review, we will perform an update compiling these new clinical, genetic and functional data recently published. We will suggest guidelines for the practice of the phaeochomocytoma genetic testing in the patients and their families, and for an early detection of tumors in the patients or in individuals determined to be at-risk of disease by the presymptomatic genetic testing
Key words
Adrenocortical tumor - Li-Fraumeni syndrome - Beckwith-Wiedemann syndrome - Multiple endocrine neoplasia type 1 - Carney complex - Paraganglioma - Pheochromocytoma
References
Molecular genetics of adrenal tumours. In: John A H Wass, Stephen M Shalet (eds) Oxford textbook of Endocrinology and Diabetes. Oxford; Oxford University press 2002: 831-842
PRKAR1A gene in patients with the Carney complex.
Hum Mol Genet.
2000;
9
3037-3046
PRKAR1A ) gene in patients with Carney complex and primary pigmented nodular adrenocortical disease (PPNAD) reveals novel mutations and clues for pathophysiology: augmented PKA signaling is associated with adrenal tumorigenesis in PPNAD.
Am J Hum Genet.
2002;
71
1433-1442
PRKAR1A gene in Cushing’s syndrome due to sporadic primary pigmented nodular adrenocortical disease.
J Clin Endocrinol Metab.
2002;
87
4324-4329
PRKAR1A and its locus (17q22 - 24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity.
Cancer Res.
2003;
63
5308-5319
SDHD , a mitochondrial complex II gene, in hereditary paraganglioma.
Science.
2000;
287
848-851
SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma.
Am J Hum Genet.
2001;
69
49-54
SDH C cause autosomal dominant paraganglioma, type 3.
Nat Genet.
2000;
26
268-270
SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway.
Am J Hum Genet.
2001;
69
1186-1197
SDHB gene mutation in an apparently sporadic pheochromocytoma.
J Clin Endocrinol Metab.
2002;
87
4771-4774
SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas.
Cancer Res.
2003;
63
5615-5621
SDHB and VHL genes should be systematically tested in patients with nonsyndromic pheochromocytoma.
J Hypertens.
2004;
22 (suppl 2)
S210
SDHD MII mutation in a second Chinese family: a founder effect?.
Laryngoscope.
2003;
113
1055-1058
SDHD mutations in carotid body tumors and pheochromocytomas: paraganglioma syndrome type 1.
Curr Opin Endocrinol Diabetes.
2003;
10
197-204
SDHD , a mitochondrial complex II gene, in nonfamilial pheochromocytoma.
Cancer Research.
2000;
60
6822-6825
SDHD mutation in familial phaechromocytoma.
Lancet.
2001;
357
1181-1182
SDHB ) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas.
Oncogene.
2003;
22
1358-1364
SDHD , SDHB and SDH C in paraganglioma and phaeochromocytoma susceptibility.
Clin Endocrinol.
2003;
59
728-733
jerome.bertherat@cch.ap-hop-paris.fr
